Edition:
United States

ChemoCentryx Inc (CCXI.OQ)

CCXI.OQ on NASDAQ Stock Exchange Global Select Market

6.90USD
26 May 2017
Change (% chg)

$-0.07 (-1.00%)
Prev Close
$6.97
Open
$6.94
Day's High
$7.11
Day's Low
$6.70
Volume
23,766
Avg. Vol
42,193
52-wk High
$9.09
52-wk Low
$3.95

CCXI.OQ

Chart for CCXI.OQ

About

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving... (more)

Overall

Beta: 1.48
Market Cap(Mil.): $332.40
Shares Outstanding(Mil.): 48.17
Dividend: --
Yield (%): --

Financials

  CCXI.OQ Industry Sector
P/E (TTM): -- 14.27 17.41
EPS (TTM): -0.65 -- --
ROI: -36.17 -7.17 -5.42
ROE: -57.87 -6.63 -4.68

BRIEF-Chemocentryx Q1 revenue $8.2 million

* Chemocentryx Inc- Expects to utilize cash and cash equivalents between $50 million and $55 million in 2017

May 10 2017

BRIEF-Chemocentryx receives FDA orphan drug designation for Avacopan in treatment of debilitating kidney disease

* Chemocentryx receives fda orphan drug designation for avacopan in the treatment of debilitating kidney disease c3 glomerulopathy (c3g)

Mar 22 2017

BRIEF-Chemocentryx reports Q4 revenue of $4.9 mln

* Chemocentryx Inc - company expects to utilize cash and cash equivalents between $50 million and $55 million in 2017

Mar 14 2017

BRIEF-Vifor Pharma, ChemoCentryx announce expansion of Avacopan agreement

* Vifor Pharma and ChemoCentryx announce expansion of avacopan agreement for rare renal diseases

Feb 14 2017

More From Around the Web

Competitors

Earnings vs. Estimates